Impressive and sustained success in using tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML), and trials showing some patients can safely stop therapy without relapse, has prompted a push to take the practice into the mainstream setting. Leading haematologists also want to see the establishment of guidelines to define the best strategies for ...
Treatment free remission closer to a reality in CML
By Amanda Sheppeard
8 Aug 2016